Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.